Onyx Biotec Limited IPO
Open SmeCurrent GMP
₹5 (+8.20%)
Price Band
₹ 58 – 61
Lot Size
2000
Issue Size
₹29.34 Cr
Minimum Investment
₹244000 (4000 Shares)
Listing Date
21 November 2024
Subscription
198.08x
About the Company
Onyx Biotec Limited, originally incorporated as Onyx Biotec Private Limited in 2005, was converted into a public limited company in 2024, adopting its current name. The company operates in the pharmaceutical industry, specializing in the manufacture and supply of sterile pharmaceutical products, including Sterile Water for Injections, Dry Powder Injections, and Dry Syrup. It also acts as a contract manufacturer for a range of pharmaceutical products for both domestic and international markets.
Core Business and Products:
- Sterile Water for Injections: Onyx Biotec started operations in 2010 with this product and has grown to become a prominent supplier to major pharmaceutical companies in India.
- Dry Powder Injections and Dry Syrups: The company manufactures these products for various pharmaceutical companies and healthcare providers in India and abroad.
- Contract Manufacturing: Onyx provides end-to-end product development and manufacturing solutions, including regulatory filing support for both Indian and global markets.
Manufacturing Facilities: Onyx operates two manufacturing units in Himachal Pradesh:
- Unit I: Located in Ropar, it has a capacity of producing 638,889 units of Sterile Water for Injections per day.
- Unit II: Located in Nalagarh, it has a production capacity of 40,000 units of Dry Powder Injections and 26,667 units of Dry Syrup per day (in a single shift).
Both units are equipped with modern equipment, follow sustainable practices, and are accredited by global regulatory agencies, including WHO-GMP (Good Manufacturing Practices). These facilities undergo regular audits by clients and regulators to ensure adherence to quality standards.
Key Clients: Onyx has established long-term relationships with leading pharmaceutical companies, including:
- Hetero Healthcare Limited
- Mankind Pharma Limited
- Sun Pharmaceutical Industries Limited
- Aristo Pharmaceuticals Private Limited
- Macleods Pharmaceuticals Limited
- Axa Parenterals Limited
- FDC Limited
- Zuventus Healthcare Limited
- Akums Drugs and Pharmaceuticals Limited
- Reliance Life Sciences Limited
Onyx Biotec Limited is a growing player in the pharmaceutical manufacturing sector, known for its high-quality sterile products and strong client relationships. The company is focused on expanding its capabilities through strategic investments in manufacturing upgrades and packaging technology, aiming to strengthen its market position both in India and internationally.
Promoters
- Sanjay Jain
- Naresh Kumar
- Fateh Pal Singh
Promoters Holding
Holding Pre Issue
88.60%
Holding Post Issue
0.00%
Objects of the Issue
The Company proposes to utilize the Net Proceeds from the Issue towards the following objects:
- Upgradation of existing manufacturing Unit I to manufacture large volume parentals for intravenous use.
- Setting up a high-speed cartooning packaging line at existing manufacturing Unit II for Dry Powder Injections.
- Prepayment or repayment of all or a portion of certain loans availed by the Company.
- General Corporate Purposes.
Address / Contact Info
Onyx Biotec Limited
Bir Plassi Near Sainimajraropar,
Nalagarh Road, District Solan –
174 101, Himachal Pradesh
Phone: +91 172 265 6384
Email: generalinfo@onyxbiotec.com
Website: http://www.onyxbiotec.com
IPO Snapshot
IPO Timeline (Tentative)
IPO Open Date
Wednesday, 13 November 2024
IPO Close Date
Monday, 18 November 2024
Basis of Allotment
Tuesday, 19 November 2024
Initiation of Refunds
Wednesday, 20 November 2024
Credit of Shares to Demat
Wednesday, 20 November 2024
Listing Date
Thursday, 21 November 2024 — NSE & BSE
Important Dates
Open Date
13 November 2024
Close Date
18 November 2024
Basis Of Allotment
19 November 2024
Listing Date
21 November 2024
Financial Performance (₹ in Crores)
| Particular | 31 May 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 7476.57 | 7413.58 | 5872.36 | 3683.84 |
| Revenue | 1054.11 | 5387.43 | 3961.65 | 4498.09 |
| Profit After Tax | 130.77 | 303.16 | 184.46 | 335.29 |
| Net Worth | 2618.64 | 2487.87 | 1820.16 | 1637.59 |
| Reserve & Surplus | 1286.42 | 1155.65 | 1230 | 1047.43 |
| Total Borrowings | 3156.14 | 3078.04 | 2922.83 | 1224.39 |
EPS Pre
2.28%
EPS Post
4.33%
P/E Pre
26.81
P/E (Post Issue)
14.10x
Company Financial Information
KPI Information (₹ in Crores)
| Particular | KPI as of May 31, 2024. |
|---|---|
| ROE % | 3.71 |
| ROCE % | 4.99 |
| Debt / Equity | 0 |
| RoNW % | 4.99 |
| PbW | 0 |
| Pat Margin % | 12.42 |
Return Ratio
IPO Reservations
| Category | Shares Offered | Shares Offered % | Max Allotee |
|---|---|---|---|
| Anchor Investors | 1366000 | 28.4 | 0 |
| Market Maker | 244000 | 5.07 | 0 |
| Qualified Institutions | 912000 | 18.96 | 0 |
| Non-Institutional | 688000 | 14.3 | 0 |
| Retail Investors | 1600000 | 33.26 | 0 |
| Total | 4810000 | 100 | 0 |
Subscription Status ( Mon, 18 Nov 24 12:56 PM)
| Category | Shares Offered | Shares Bid For | Subscription (x) |
|---|---|---|---|
| Qualified Institutions | 912000 | 29634000 | 32.49x |
| Non-Institutional | 688000 | 415012000 | 603.22x |
| Retail Investors | 1600000 | 189210000 | 118.26x |
| Total | 3200000 | 633856000 | 198.08x |
Subscription figures are updated periodically and may change until issue closing. Data reflects bids placed across exchanges.
Peer Comparision
No Peer Comparision Available
Lot Size & Investment Details
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 2,000 | 122,000.00 |
| Retail (Max) | 1 | 2,000 | 122,000.00 |
| S-HNI (Min) | 2 | 4,000 | 244,000.00 |
Book Running Lead Managers
RHP Document
DRHP Document
Disclaimer: This data is for informational purposes only and does not constitute investment advice. Figures shown are illustrative sample data.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
Onyx Biotec Limited IPO is a Book-building IPO worth ₹29.34 crores. The price band is ₹58 to 61 per share. The IPO opens on Wed, Nov 13, 2024 and closes on Mon, Nov 18, 2024. It will be listed on BSE and NSE. Mas Services Limited is the registrar.
The Onyx Biotec Limited IPO opens on Wed, Nov 13, 2024 and closes on Mon, Nov 18, 2024
Onyx Biotec Limited IPO Price Band is ₹58 to 61.
Onyx Biotec Limited IPO lot size is 2000, and the minimum amount required for application is ₹244000.
The minimum investment for Onyx Biotec Limited IPO is approximately ₹244000 based on the upper price band.
To apply for the Onyx Biotec Limited IPO, investors can use the ASBA (Application Supported by Blocked Amount) process via their bank's net banking or apply through UPI using a registered broker or trading app. The IPO is available in retail, HNI, and institutional investor categories. Investors must select the lot size, enter bid details within the price band, and submit their application before the IPO closing date of Mon, Nov 18, 2024. After submission, funds are blocked until the basis of allotment of Onyx Biotec Limited IPO is finalised.
Onyx Biotec Limited IPO issue size is ₹29.34 crores.
Onyx Biotec Limited IPO allotment date is Sat, Jun 27, 2026.
The registrar for Onyx Biotec Limited IPO is Mas Services Limited. Investors can go to Mas Services Limited website for IPO allotment status, refund processing, and other queries related to Onyx Biotec Limited IPO through their official website or helpline.
The Onyx Biotec Limited IPO GMP (Grey Market Premium) is ₹5 as of Fri, Nov 22, 2024. Based on the upper price band of ₹61 per share, the estimated Onyx Biotec Limited IPO listing price is ₹66, indicating a potential listing gain of approximately 31% over the issue price.